健康成人接种含与不含AS03佐剂的第五波甲型H7N9灭活疫苗不同剂量的免疫原性与安全性
这项2期双盲试验将720名≥19岁成人随机分配,接种两剂(间隔21天)长江三角洲谱系甲型H7N9灭活疫苗,含AS03A佐剂者HA剂量为3.75、7.5、15 µg,不含佐剂者为15、45 µg。两剂含佐剂15 µg疫苗后抗疫苗株HI滴度≥40者占65%,不含佐剂组为0%;含佐剂组19-64岁为76%、≥65岁为49%。AS03佐剂改善免疫应答,尤其年轻成人,但对漂移株应答减弱,疫苗总体耐受良好。
要点
- 两剂含佐剂15 µg疫苗后HI滴度≥40者占65%,不含佐剂组为0%。
- 含佐剂15 µg组HI滴度≥40者19-64岁为76%,≥65岁为49%。
- 含佐剂疫苗应答不随HA含量变化,抗体随时间下降,对漂移株应答减弱。
核心结论
- AS03佐剂改善第五波H7N9灭活疫苗的免疫应答,尤其年轻成人,但对漂移H7N9株应答较低。
研究设计与样本
- 2期双盲试验随机分配720名≥19岁成人,接种两剂(间隔21天)长江三角洲谱系甲型H7N9灭活疫苗。
- 含AS03A佐剂组HA剂量为3.75、7.5、15 µg,不含佐剂组为15、45 µg。
主要发现
- 两剂含佐剂15 µg疫苗后抗疫苗株HI滴度≥40者占65%(95%CI 57%-73%),不含佐剂15 µg组为0%(95%CI 0%-4%)。
- 含佐剂15 µg组HI滴度≥40者19-64岁为76%(95%CI 66%-84%),≥65岁为49%(95%CI 37%-62%)。
- 含佐剂疫苗应答不随HA含量变化,抗体随时间下降,对漂移H7N9株应答减弱。
- 疫苗总体耐受良好,含佐剂疫苗与更频繁的征集性全身和局部不良事件相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human infections with the avian influenza A(H7N9) virus were first reported in China in 2013 and continued to occur in annual waves. In the 2016/2017 fifth wave, Yangtze River Delta (YRD) lineage viruses, which differed antigenically from those of earlier waves, predominated. METHODS: In this phase 2 double-blinded trial we randomized 720 adults ≥ 19 years of age to receive two injections of a YRD lineage inactivated A/Hong Kong/125/2017 fifth-wave H7N9 vaccine, given 21 days apart, at doses of 3.75, 7.5, and 15 µg of hemagglutinin (HA) with AS03A adjuvant and at doses of 15 and 45 µg of HA without adjuvant. RESULTS: Two doses of adjuvanted vaccine were required to induce HA inhibition (HI) antibody titers ≥ 40 in most participants. After two doses of the 15 µg H7N9 formulation, given with or without AS03 adjuvant, the proportion achieving a HI titer ≥ 40 against the vaccine strain at 21 days after the second vaccination was 65 % (95 % CI, 57 %-73 %) and 0 % (95 % CI, 0 %-4%), respectively. Among those who received two doses of the 15 µg adjuvanted formulation the proportion with HI titer ≥ 40 at 21 days after the second vaccination was 76 % (95 % CI, 66 %-84 %) in those 19-64 years of age and 49 % (95 % CI, 37 %-62 %) in those ≥ 65 years of age. Responses to the adjuvanted vaccine formulations did not vary by HA content. Antibody responses declined over time and responses against drifted H7N9 strains were diminished. Overall, the vaccines were well tolerated but, as expected, adjuvanted vaccines were associated with more frequent solicited systemic and local adverse events. CONCLUSIONS: AS03 adjuvant improved the immune responses to an inactivated fifth-wave H7N9 influenza vaccine, particularly in younger adults, but invoked lower responses to drifted H7N9 strains. These findings may inform future influenza pandemic preparedness strategies.
引用
- Jackson LA, Stapleton JT, Walter EB, et al. Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults. Vaccine. 2023. PMID: 38105137. doi:10.1016/j.vaccine.2023.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。